4,7,11-trioxa-16-azatetracyclo[8.7.0.03,8.012,16]heptadeca-1,3(8),9-trien-17-one

• ChemBase编号: 126768
• 分子式: C13H13NO4
• 平均质量: 247.24662
• 单一同位素质量: 247.0844579
• SMILES: C1CC2N(C1)C(=O)c1cc3c(cc1O2)OCCO3
• Canonical SMILES: O=C1N2CCCC2Oc2c1cc1OCCOc1c2
• InChI: InChI=1S/C13H13NO4/c15-13-8-6-10-11(17-5-4-16-10)7-9(8)18-12-2-1-3-14(12)13/h6-7,12H,1-5H2
• InChIKey: RQEPVMAYUINZRE-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 4,7,11-trioxa-16-azatetracyclo[8.7.0.0^3,^8.0^1^2,^1^6]heptadeca-1,3(8),9-trien-17-one
• IUPAC传统名: 4,7,11-trioxa-16-azatetracyclo[8.7.0.0^3,^8.0^1^2,^1^6]heptadeca-1,3(8),9-trien-17-one
• 别名: CX-614; CX614; 2,3,6a,7,8,9-Hexahydro-11H-1,4-dioxino[2,3-g]pyrrolo[2,1-b][1,3]benzoxazin-11-one; CX 614; LiD 37; BDP 37

登记号

• CAS号: 191744-13-5
• PubChem SID: 162221096
• PubChem CID: 6451148
• 美国药典/FDA物质标识码: 87V631480W
• 维基百科标题: CX614

理论计算性质

• 质子受体: 4
• 质子供体: 0
• LogD (pH = 5.5): 0.9581486
• LogD (pH = 7.4): 0.95814866
• Log P: 0.95814866
• 摩尔折射率: 62.7704 cm^3
• 极化性: 24.123209 Å^3
• 极化表面积: 48.0 Å^2
• 可自由旋转的化学键: 0
• 里宾斯基五规则: true

分子性质

理化性质

• 溶解度: Chloroform; DMSO; Methanol
• 外观: White to Off-White Solid
• 熔点: 149-151°C

安全信息

• 保存条件: Refrigerator

药理学性质

• 法定药品分级: Investigational New Medicine

详细说明

Toronto Research Chemicals - B129500

It is one of a series of AMPA modulators for the potential treatment of Alzheimer's disease, schizophrenia, and mild cognitive impairment (MCI). An ampakine drug that facilitates activation of glutamatergic AMPA receptors.

参考文献

• Arai, A., et al.: J. Pharmacol. Exp. Ther., 278, 627 (1996)
• Marini, A., et al.: J. Biol. Chem., 273, 29394 (1996)
• Balkowiec, A., et al.: J. Neurosci., 22, 10399 (1996)
• Dicou, E., et al.: Brain Res., 970, 221 (1996)